Headlines about Anika Therapeutics (NASDAQ:ANIK) have been trending somewhat positive on Wednesday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anika Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.2275235049083 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Anika Therapeutics (NASDAQ ANIK) opened at $58.36 on Wednesday. The stock has a market cap of $855.66, a P/E ratio of 27.53, a P/E/G ratio of 3.43 and a beta of 1.44. Anika Therapeutics has a 1 year low of $41.64 and a 1 year high of $60.29.
Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.05. The firm had revenue of $27.18 million during the quarter, compared to the consensus estimate of $27.44 million. Anika Therapeutics had a net margin of 28.23% and a return on equity of 13.40%. The company’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 EPS. research analysts anticipate that Anika Therapeutics will post 1.9 earnings per share for the current year.
A number of research firms recently issued reports on ANIK. Barrington Research reissued a “buy” rating and set a $57.00 target price on shares of Anika Therapeutics in a research report on Thursday, December 28th. BidaskClub raised shares of Anika Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 27th.
In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total value of $286,020.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Charles H. Sherwood sold 22,228 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $60.06, for a total value of $1,335,013.68. Following the completion of the transaction, the chief executive officer now owns 158,297 shares of the company’s stock, valued at approximately $9,507,317.82. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,469 shares of company stock valued at $1,980,733. Corporate insiders own 6.57% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Anika Therapeutics (ANIK) Receives Media Impact Score of 0.21” was published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://transcriptdaily.com/2018/01/17/anika-therapeutics-anik-receives-media-impact-score-of-0-21.html.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.